Health and wellbeing

Health and well-being have a central role in the 17 Sustainable Development Goals (SDGs) endorsed by the United Nations, emphasizing the integral part they play in building a sustainable future. The third SDG explicitly calls for ensuring healthy lives and promoting well-being for all at all ages. This goal encompasses a wide range of health objectives, from reducing maternal and child mortality rates, combatting disease epidemics, to improving mental health and well-being. But beyond SDG 3, health is intrinsically linked with almost all the other goals.

When addressing SDG 1, which aims to end poverty, one cannot neglect the social determinants of health. Economic hardship often translates into poor nutrition, inadequate housing, and limited access to health care, leading to a vicious cycle of poverty and poor health. Similarly, achieving SDG 2, ending hunger, also contributes to better health through adequate nutrition, essential for physical and mental development and the prevention of various diseases.

Conversely, the repercussions of climate change, encapsulated in SDG 13, profoundly impact health. Rising global temperatures can lead to increased spread of infectious diseases, compromised food and water supplies, and increased frequency and intensity of extreme weather events, all posing severe health risks. Conversely, the promotion of good health can also mitigate climate change through the reduction of carbon-intensive lifestyles and adoption of healthier, more sustainable behaviors.

SDG 5, advocating for gender equality, also has substantial health implications. Ensuring women's access to sexual and reproductive health services not only improves their health outcomes, but also contributes to societal and economic development. Furthermore, achieving SDG 4, quality education, is also critical for health promotion. Education fosters health literacy, empowering individuals to make informed health decisions, hence improving overall community health.

Lastly, SDG 17 underlines the importance of partnerships for achieving these goals. Multi-sector collaboration is vital to integrate health considerations into all policies and practices. Stakeholders from various sectors, including health, education, agriculture, finance, and urban planning, need to align their efforts in creating sustainable environments that foster health and well-being.

Hence, the relationship between health, well-being, and the SDGs is reciprocal. Improving health and well-being helps in achieving sustainable development, and vice versa. In this context, health and well-being are not just outcomes but are also powerful enablers of sustainable development. For the world to truly thrive, it must recognize and act upon these interconnections.

Building and Environment will host a series of free webinars on COVID-19 Control. The second webinar of the series will feature 2 presentations from experts in the field on the following topics: COVID-19 and indoor and outdoor sports, presented by Bert Blocken, Professor of Civil Engineering, Eindhoven University of Technology, the Netherlands & KU Leuven, Belgium. Efficient reduction of airborne transmission by advanced ventilation, presented by Arsen K. Melikov, Professor of Ventilation and Air Distribution, Technical University of Denmark, Denmark.
Elsevier,

Behavioural Brain Research, Volume 400, 26 February 2021

AMPK plays a key role in both diabetes mellitus (DM) and Alzheimer's disease (AD) - targeting this biomolecule and understanding the relationship with DM provides new hope for the treatment of AD
Schematic representation of the mechanism by which readthrough compounds restore channel function in G542X-CFTR–expressing cells. PTC refers to the premature termination codon.
Cystic fibrosis (CF) is caused by a mutation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, which disrupts an ion channel involved in hydration maintenance via anion homeostasis. Nearly 5% of CF patients possess one or more copies of the G542X allele, which results in a stop codon at residue 542, preventing full-length CFTR protein synthesis. Identifying small-molecule modulators of mutant CFTR biosynthesis that affect the readthrough of this and other premature termination codons to synthesize a fully functional CFTR protein represents a novel target area of drug discovery. We describe the implementation and integration for large-scale screening of a homogeneous, 1536-well functional G542X-CFTR readthrough assay. The assay uses HEK 293 cells engineered to overexpress the G542X-CFTR mutant, whose functional activity is monitored with a membrane potential dye. Cells are co-incubated with a CFTR amplifier and CFTR corrector to maximize mRNA levels and trafficking of CFTR to the cell surface. Compounds that allow translational readthrough and synthesis of functional CFTR chloride channels are reflected by changes in membrane potential in response to cAMP stimulation with forskolin and CFTR channel potentiation with genistein. Assay statistics yielded Z′ values of 0.69 ± 0.06. As further evidence of its suitability for high-throughput screening, we completed automated screening of approximately 666,000 compounds, identifying 7761 initial hits. Following secondary and tertiary assays, we identified 188 confirmed hit compounds with low and submicromolar potencies. Thus, this approach takes advantage of a phenotypic screen with high-throughput scalability to identify new small-molecule G542X-CFTR readthrough modulators.
An article on the long-term risk of dementia, in the context of SDG 3, focusing specifically on the association between dementia onset and reduced participation in cognitive and social activities.
This book chapter advances SDG #3 and #10 by providing a brief history of PET imaging and the radiotracers that have had a significant impact for measuring the three signature AD-related neuropathologies related to AD and provides an overview of the research utilizing PET imaging in the DS population
This book chapter advances SDG #3 and #10 by discussing the advantages of performing genetic studies in people with DS, and then discussing the role of reported genes that are known to be associated with AD risk in adults with DS or in the general population. It also discusses how future longitudinal multiomic and imaging study can enhance our understanding of the biology of AD.
Elsevier,

Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by discussing the operational aspects of deep learning solutions for Alzheimer’s disease, including the review of the advantages and limitations of using deep learning, and future directions on the applications of deep learning to Alzheimer’s disease.
This book chapter advances SDG #3 and #10 by systematically appraises the concepts and promising benefits of AI technology within healthcare for AD risk prediction across communities, and its possible concerns to be tackled prior to large-scale implementation.
Elsevier,

Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by outlining the applications of big data to Alzheimer’s disease research as well as common methods used to collect and analyze big data. It also explores how big data research could be used to treat, diagnose, and understand Alzheimer’s disease.
Elsevier,

Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021

This book chapter advances SDG #3 and #10 by providing evidence that behavioral treatments are more effective than most pharmacological therapies at managing depression in Alzheimer’s disease.

Pages